Buccastem

Quick links to important sections

Buccastem

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Buccastem

Quick Facts

Property Description
Active ingredient Prochlorperazine maleate
Form Buccal tablet
Pharmacological class Antiemetic, Dopamine D₂-receptor antagonist
Common use Relief from nausea, vomiting, and dizziness
Origin Synthetic

What Type of Medicine is Buccastem?

Buccastem is the trade name for a medicine containing the active component Prochlorperazine maleate, which functions primarily as an antiemetic to relieve symptoms of sickness. Pharmacologically, Prochlorperazine is classified as a phenothiazine derivative and a potent dopamine D₂-receptor antagonist. This classification defines its core mechanism, indicating that it works by interfering with dopamine signals in the central nervous system. As a substance synthesized in a laboratory, Prochlorperazine is of synthetic origin and is used as a single-ingredient medicine. Buccastem has established recognition in medical practice as a compound used for managing severe sickness, particularly in adults and adolescents.


Understanding the Buccal Tablet Formulation

The medicine is commonly presented as a buccal tablet, a specialized solid dosage form designed for transmucosal absorption; it is placed between the upper gum and the inner cheek, where it dissolves. The unique buccal route of administration is a key feature of the Buccastem brand, allowing the active component to be absorbed directly into the bloodstream through the cheek lining. This specific formulation is clinically valuable because the rapid absorption method is intended for individuals experiencing acute nausea or vomiting who may be unable to swallow or retain standard oral tablets.


General Purpose and High-Level Action

The general purpose of Buccastem is to relieve and prevent feelings of sickness by addressing the central causes of nausea and vomiting. By acting as a D₂-receptor antagonist, Prochlorperazine blocks the signals that trigger sickness in the brain's specialized area, the chemoreceptor trigger zone (CTZ). The drug also influences the vestibular (balance) centers of the brain, meaning its general use extends to helping alleviate the sensation of vertigo and dizziness associated with disturbances of the inner ear.

What side effects are possible with Buccastem?

Possible Side Effects and Safety Information

Official regulatory documents classify the safety profile of Buccastem (Prochlorperazine maleate) based on its activity as a phenothiazine derivative. The most very common adverse reaction is drowsiness (sedation). Common effects primarily involve the nervous system, known as Extrapyramidal Symptoms (EPS), which can manifest as restlessness (akathisia), involuntary muscle movements (dystonia), or features resembling Parkinsonism.


Serious and Systemic Safety Concerns

The label details serious adverse reactions that are rare but clinically significant. These include Neuroleptic Malignant Syndrome (NMS), a potentially fatal condition characterized by high fever, muscle rigidity, and autonomic instability. Tardive Dyskinesia (TD), a syndrome of potentially irreversible involuntary movements, is associated with the duration of treatment and cumulative dose.

Cardiovascular risks, such as QT prolongation and cardiac arrhythmias, are also documented. Rare systemic effects include blood dyscrasias (severe blood disorders, like agranulocytosis) and jaundice.


Population-Specific Safety and Limitations

Safety statements include specific considerations for patient populations. Older adults treated for dementia-related psychosis have an increased risk of mortality and cerebrovascular events (stroke). Neonates exposed during the third trimester of pregnancy are at risk for extrapyramidal and withdrawal symptoms after birth.

The antiemetic action of Prochlorperazine is officially noted as a safety limitation, as it may mask signs and symptoms of other underlying severe conditions, such as brain tumors or intestinal obstruction.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents describe that overdose of Prochlorperazine maleate (Buccastem) can lead to severe and potentially life-threatening clinical manifestations. The primary systems affected are the Central Nervous System (CNS) and the Cardiovascular System.

Overdose may present with profound drowsiness, agitation, confusion, and a loss of consciousness that can progress to coma. Documented neuromuscular effects include seizures and characteristic involuntary muscle movements, known as dystonic reactions. Serious outcomes involve severe hypotension (critically low blood pressure) and dangerous cardiac arrhythmias (irregular heartbeats) that necessitate continuous monitoring.

Required Emergency Actions

Government guidance mandates that individuals experiencing any severe symptoms—such as convulsions, difficulty breathing, or changes in heart rhythm—must seek immediate medical attention and contact emergency services.

Treatment is officially defined as symptomatic and supportive. Regulatory labeling states that no specific antidote is known. Management procedures may include the administration of activated charcoal and the use of specific vasoconstrictors like Norepinephrine to address severe hypotension, while explicitly advising that Epinephrine is contraindicated.

Population-Specific Note: Regulatory sources caution that Prochlorperazine should be avoided in children and adolescents whose symptoms suggest Reye's syndrome, as its antiemetic action can mask critical CNS signs of that condition.

Therapeutic Uses of Buccastem

What Buccastem Treats: Main Uses and Benefits

Buccastem (Prochlorperazine maleate) is commonly used for symptomatic relief across core therapeutic domains, primarily managing sickness and addressing certain balance disturbances. It is applied in clinical settings where supportive symptomatic management is appropriate during acute or episodic manifestations.

The medicine is commonly used to help with symptom clusters that may become intense or disruptive. The primary therapeutic uses include the relief of severe nausea and vomiting, as well as the management of vertigo and associated dizziness. It is considered relevant in conditions characterized by periods of heightened symptoms, such as sickness associated with migraines or certain labyrinthine disorders.

“The support provided may contribute to easing the overall symptom load during episodes of intense sickness.”


Control of Sickness and Balance

This medicine is applied in scenarios where additional management of discomfort is required, such as when balance symptoms become temporarily overwhelming or severe sickness creates noticeable interference with daily stability. It offers symptomatic relief that may help patients cope more steadily with difficult episodes, and may assist with maintaining the patient's capacity for oral fluid intake.


Quick Fact: Relief for Key Symptoms
Main Use Categories Severe Nausea, Vomiting, Vertigo, Dizziness
Primary Benefit Easing overall symptom load and supporting stability
Context Acute episodes, inner ear disorders, migraine-associated sickness

Eligibility and Restrictions for Use

Who Can and Cannot Use Buccastem?

Regulatory eligibility for Buccastem (Prochlorperazine maleate) is strictly defined by age, pre-existing health conditions, and physiological status.


Contraindicated Populations

Buccastem is contraindicated (must not be used) in patients with specific health conditions, as stated in official labeling:

  • Known hypersensitivity to phenothiazines or the active substance.
  • Existing blood dyscrasias or bone marrow depression.
  • Impaired liver function or history of phenothiazine-related jaundice.
  • Parkinson's Disease, Phaeochromocytoma, or narrow angle glaucoma.
  • Patients in comatose states or experiencing severe CNS depression.
  • Elderly patients with dementia-related psychosis (use is not approved).

Age-Related Eligibility and Restrictions

Age Group Eligibility Status
Children under 2 years Contraindicated.
Adolescents (Buccal form) Generally for ages 18 and over (some regions).
Older Adults Use is not approved for those with dementia-related psychosis.

Use during Pregnancy and Lactation

Use is not recommended during pregnancy, particularly in the third trimester due to risk of neonatal withdrawal symptoms. It is also not recommended for women who are breastfeeding, as the substance may pass into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Prochlorperazine maleate (Buccastem) is defined by specific pharmacodynamic and pharmacokinetic patterns documented in government regulatory information. This profile is structured by substances that are formally contraindicated, restricted, or which alter drug exposure.

Contraindicated and Restricted Combinations

  • Central Nervous System (CNS) Depressants: Co-administration with large amounts of substances that depress the CNS, including alcohol, narcotics, and barbiturates, is a formal contraindication due to the potential to intensify and prolong their sedative effects.
  • Cardiovascular Agents: Combination with QTc prolonging drugs is restricted because regulatory documents note an increased risk of serious ventricular arrhythmias. Furthermore, Adrenaline (Epinephrine) should not be used to treat hypotension associated with Prochlorperazine, as it may paradoxically cause a further, severe reduction in blood pressure.

Pharmacodynamic and Exposure Interactions

Category Officially Documented Interaction
Pharmacodynamic Antagonism The medicine is stated to oppose the effects of Levodopa. Combined use with antihypertensive medicines may lead to an exaggerated hypotensive effect, and anticholinergic effects may be enhanced.
Metabolic System Prochlorperazine is metabolized by the CYP450 system (CYP2D6); co-administration with other drugs affecting this enzyme requires monitoring due to potential for altered exposure.
Exposure Modification Antacids may decrease Prochlorperazine absorption, which could reduce its concentration. The efficacy of both Oral Anticoagulants and certain Anticonvulsants may also be diminished. Elderly patients are noted as being at higher risk for drug-induced Parkinsonism and orthostatic hypotension.

Mechanism of Action

Buccastem (Prochlorperazine) is a first-generation phenothiazine that acts primarily as a centrally localized D2 dopamine receptor antagonist in the brain. The drug's mechanism involves high-affinity binding to and blockade of D2 dopamine receptors, with a selective concentration of this interaction occurring within the Chemoreceptor Trigger Zone (CTZ) of the medulla.

This D2 receptor antagonism prevents dopamine from binding to its post-synaptic target, consequently attenuating the excitatory dopaminergic signal transmission originating from the CTZ. The resulting cellular cascade modulates afferent signaling that would otherwise project toward the vomiting center. Prochlorperazine also exhibits binding affinity for several other receptor types, including histaminergic H1 receptors, muscarinic cholinergic receptors, and alpha-1 adrenergic receptors.

Dosage and Administration Information

Instruction Map: How to use Buccastem — Administration Guidelines

This map summarizes the administration and dosing instructions for Buccastem (Prochlorperazine maleate buccal tablet).


Administration Scope

Instruction Entity Detail
Route of administration Buccal (Transmucosal), requiring absorption through the inner cheek lining.
Dosing schedule (Adults) Standard single dose is 3 mg. Typically one to two tablets taken twice daily.
Maximum Daily Dose Dosage must not exceed a maximum of 6 mg in a 24-hour period.
Timing in relation to meals The tablet is often instructed to be taken after meals.
Preparation requirements The tablet is used whole and must not be crushed, chewed, or swallowed whole.
Age-group administration rules Approved for use in adults aged 18 years and over; not recommended for individuals under 18 years.
Missed-dose rules If a dose is missed, the guidance is to skip the missed dose and continue with the next scheduled dose; do not double doses.
Special procedural conditions The full course of treatment is limited to a maximum of two days for acute use.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Buccal
Frequency pattern Scheduled twice daily (BD) or as needed for intermittent acute symptoms.
Basis of use Standardized administration guidelines.
Use-context constraints Limited to short-term management; maximum daily dose of 6 mg.

Resulting Procedural Structure

Step sequence:

  • Place the 3 mg buccal tablet high up along the top gum under the upper lip or cheek.
  • Allow the tablet to adhere and dissolve slowly and completely in place (a process which may take 1 to 2 hours).
  • Administer the dose once or twice daily as directed, ensuring the 6 mg maximum daily dose is not exceeded.

Connection to the overall use protocol:

The use protocol for Buccastem is defined by the unique requirement for buccal administration, mandating that the tablet must dissolve in the mouth for the active component to be absorbed correctly. This method is paired with strict 3 mg dosing and a 6 mg maximum daily limit, establishing clear constraints for the medicine’s scheduled or intermittent use over a short-term duration.

Recent Clinical Evidence

Buccastem: Recent Clinical Evidence

Evidence for use in Acute Nausea and Vomiting

Research exploring how symptoms change over time for acute sickness involves short-term, randomized controlled trials (RCTs) examining adult populations. These studies were used in research contexts involving unstable symptoms to measure patient-reported discomfort, monitoring outcomes such as changes in symptom severity and the need for further medication (documented as the need for further medication). Most initial trials evaluated the medication’s intravenous or oral forms, meaning high-quality comparative evidence for the buccal formulation specifically remains limited.

Evidence for use in Vertigo and Associated Dizziness

Prochlorperazine was evaluated in studies focusing on conditions characterized by fluctuating manifestations of dizziness and vertigo, such as inner ear disorders like labyrinthitis or Ménière's disease. These trials explored outcomes related to systemic imbalance. Observed patterns related to systemic imbalance in some studies were associated with patient-reported changes in physical discomfort (nausea and vomiting). Evidence is limited in comparing the medication to a placebo for the isolated symptom of vertigo, and research primarily focused on acute or temporary physiological imbalance.

Evidence for Nausea and Vomiting Associated with Migraine

This section describes compiled data from systematic reviews and trials that have explored the use of Prochlorperazine for symptoms of sickness that occur during an acute migraine attack. Studies explored short-term symptom changes, reporting how symptoms evolved alongside other outcomes, such as headache pain relief. Because the drug is frequently co-administered with pain relievers, attributing specific outcomes solely to Prochlorperazine can be uncertain. Most research focused on acute, single-dose administration using IV or oral formulations.

Key Areas of Scientific Uncertainty and Limitations

The available research primarily focuses on acute and short-term outcomes for all indicated uses, with long-term effects not fully established in the research record. Follow-up durations were limited across many key studies. Data for certain groups remain insufficient, as most research concentrated on adult populations, meaning limited information is available for certain groups, such as children or individuals with complex comorbidities.

Key Studies & References

  1. Comparison of Efficacy of Metoclopramide, Promethazine and Prochlorperazine in the Treatment of Peripheral Vertigo in the Emergency Department (A Triple-Blind, Randomized Controlled Trial, Multi-Centers)

Frequently Asked Questions (FAQ)

Common questions about Buccastem (FAQ)


Q: How quickly should I expect Buccastem to start working after I take it?

Regulatory information indicates the tablet is designed to dissolve slowly in the cheek over a period that may take between one and two hours. The medicine is designed for absorption through the mouth lining during this time. This method allows the medicine to enter the bloodstream without needing to be swallowed.

Q: What is the total duration of effect for one dose of Buccastem?

Official documents describe the medicine's duration of action using a pharmacokinetic parameter called the elimination half-life. The elimination half-life for prochlorperazine in this formulation is stated to be 9.0 hours, which is a key factor that influences the dosing frequency mentioned in the official instructions.

Q: Is it normal to feel a strange sensation in the mouth where the tablet was placed?

Yes, official documents list local reactions in the mouth as possible side effects. These can include irritation to the gum or mouth lining, numbness of the mouth, or a tingling, pricking, or burning sensation in the area where the tablet adheres.

Q: If I have kidney problems, is it safe to use Buccastem?

Official documentation notes that prochlorperazine, the active ingredient, should be avoided or used with caution in patients with known renal dysfunction (kidney problems). This indicates that kidney status is a regulatory consideration for use.

Q: Why might a doctor prescribe Buccastem instead of a different anti-sickness drug?

Regulatory texts highlight that the Buccastem tablet is designed for transmucosal absorption, meaning it is absorbed directly through the cheek lining without being swallowed. This unique route of administration is noted to be clinically reliable for individuals experiencing acute sickness.

Q: Is there a maximum number of days or doses I should use Buccastem in a week?

Official instructions limit the full course of treatment to a maximum of two days for acute use. The maximum daily dose is also established in regulatory documentation. Official guidelines for acute sickness do not typically cover use extending beyond this short-term period.

Q: Can Buccastem cause headaches, and is this a common side effect?

Headaches have been mentioned in official safety information, sometimes reported in conjunction with symptoms of infection or as part of a severe reaction. However, headaches are not typically listed as a common, stand-alone side effect in the regulatory summaries.

Q: Do I need a prescription to get Buccastem?

Prochlorperazine buccal tablets are available under different regulatory classifications depending on the country and product packaging. Some versions are sold only by a pharmacist (P-Medicine), while others require a prescription (Prescription-Only Medicine or POM).

Q: What evidence exists regarding Buccastem's effect on blood pressure?

Regulatory documents note that the medicine can cause low blood pressure (hypotension). Orthostatic hypotension (low blood pressure upon standing) is noted as a possible effect, particularly in elderly or volume-depleted patient groups.

Q: Is Buccastem suitable for travel sickness?

Official information indicates that Prochlorperazine is used for the management of symptoms associated with motion sickness and travel sickness. Its usage is aligned with its general purpose of alleviating nausea, vomiting, and dizziness.

Q: Can Buccastem affect blood sugar levels, according to regulatory sources?

Safety information reports that this class of medicine can potentially cause high blood sugar levels (hyperglycaemia). Regulatory information notes that patients with diabetes may need to be monitored more closely due to this potential effect.

Q: Does using Buccastem cause a metallic taste or dry mouth?

Official safety documents list dry mouth as a common possible side effect. They also mention altered or decreased ability to taste as a potential local reaction in the mouth.

Q: What is the difference between Buccastem and other prochlorperazine products?

The key functional difference is the buccal tablet formulation, which is placed in the mouth for absorption through the cheek lining. Other products containing prochlorperazine may be available in different forms, such as standard oral tablets or injections.

Q: Is Buccastem safe to use for people who have epilepsy?

Official documentation lists epilepsy as a condition where the medicine should not be used or used with caution. This is related to the drug class's potential to lower the seizure threshold, as stated in regulatory precautions.

Q: Are there any reported cases of serious allergic reactions to Buccastem?

Serious allergic reactions are described in patient information. Symptoms can include a rash, swelling of the face, throat, or tongue, and difficulty breathing or swallowing. These types of reactions are always considered immediate medical emergencies.

Q: If I feel dizzy after using Buccastem, is that a listed side effect?

Dizziness is listed as a potential side effect in regulatory documents. This can sometimes occur due to other side effects, such as low blood pressure, especially when changing position quickly.

Q: Is it normal to have a slight burning or irritation when placing the tablet?

Yes, official documents list local reactions such as irritation or a tingling, pricking, or burning sensation in the mouth as possible side effects. These are typically localized to the area where the tablet adheres.

Q: What is the general level of evidence for Buccastem's effectiveness?

The research evidence base is described as primarily focusing on acute and short-term outcomes for the approved indications in adult populations, based on randomized controlled trials. Official summaries note that long-term effects are not fully established in the available research record.

Q: Do health bodies officially restrict the use of Buccastem in certain situations?

Official documents detail several precautions and restrictions. These include avoiding co-administration with other Central Nervous System (CNS) depressants, such as alcohol, advising caution when driving or operating machinery, and suggesting patients avoid exposure to direct sunlight.

Q: Is the ingredient in Buccastem used in any other types of medication?

Yes, the active ingredient, prochlorperazine, is a phenothiazine derivative. In other formulations (non-buccal), this compound is also used to treat specific symptoms of mental health disorders, such as schizophrenia and anxiety.

Q: How is the safety profile of Buccastem described in official regulatory summaries?

The safety profile in official summaries details a range of possible effects. The most common reaction is drowsiness, and the profile also includes information on rare but serious risks, such as Neuroleptic Malignant Syndrome and effects on the heart rhythm.

Q: Will I feel sleepy or drowsy after using Buccastem?

Regulatory documents state that drowsiness (sedation) is the most very common adverse reaction associated with the use of this medicine. This effect is expected due to the drug’s activity on the central nervous system.

Q: What are the most common side effects people report when using Buccastem?

The most commonly reported effects include drowsiness and those related to the nervous system, known as Extrapyramidal Symptoms (EPS). EPS can manifest as restlessness or involuntary muscle movements.

Q: Is there a risk of developing involuntary movements (like twitching) with Buccastem?

Official safety information includes the risk of involuntary muscle movements, such as those associated with Extrapyramidal Symptoms (EPS). It also mentions the risk of Tardive Dyskinesia (TD), a potentially irreversible condition linked to treatment duration.

Q: What is the difference between Buccastem and other anti-sickness tablets?

This medicine belongs to the phenothiazine class, working by blocking dopamine receptors in the brain's sickness center. The key functional difference from many other anti-sickness medicines is its unique buccal route of administration through the cheek.

Q: What does the research say about how effective Buccastem is for different types of nausea?

Studies have primarily focused on the effectiveness of Prochlorperazine for the short-term management of acute nausea and vomiting, symptoms associated with vertigo and inner ear disorders, and sickness related to migraine attacks.

Q: Is it possible to become dependent on Buccastem if I use it frequently?

Regulatory information notes that abrupt cessation, particularly after long-term use or high doses, may rarely result in withdrawal symptoms such as nausea, vomiting, or dizziness. This is the reason official guidance addresses the potential need for gradual cessation.

Q: Can I use Buccastem if I am feeling sick due to a migraine?

Yes, regulatory documents list this medicine as intended for treating nausea and vomiting that is specifically associated with a previously diagnosed migraine attack.

How should Buccastem be stored and disposed of?

Storage and Disposal Requirements for Buccastem M

Buccastem M Buccal Tablets must be stored and handled according to official regulatory specifications to maintain the quality of this solid dosage form.

Storage Category Official Requirement
Temperature Store below 25°C in a dry place.
Protection Keep the tablets in the outer carton and original container to protect from light.
Child Safety Keep this medicine out of the sight and reach of children.
Expiry Do not use the tablets after the expiry date (EXP) shown on the packaging.
Disposal Rule Dispose of any unused product or waste material in accordance with local requirements.

Official labeling mandates keeping the medicine in its original packaging for light protection and ensuring it is inaccessible to children. Furthermore, the unused or expired product must not be disposed of via wastewater or household waste, requiring compliance with specific pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Buccastem found in:

A-Z Index: